NO20044672L - Parenteral, intravenos og oral administrering av oksazolidinoner for behandling av diabetiske fotinfeksjoner - Google Patents

Parenteral, intravenos og oral administrering av oksazolidinoner for behandling av diabetiske fotinfeksjoner

Info

Publication number
NO20044672L
NO20044672L NO20044672A NO20044672A NO20044672L NO 20044672 L NO20044672 L NO 20044672L NO 20044672 A NO20044672 A NO 20044672A NO 20044672 A NO20044672 A NO 20044672A NO 20044672 L NO20044672 L NO 20044672L
Authority
NO
Norway
Prior art keywords
parenteral
intravenous
diabetic foot
oxazolidinones
treatment
Prior art date
Application number
NO20044672A
Other languages
English (en)
Norwegian (no)
Inventor
Carl Norden
Original Assignee
Pharmacia & Upjohn Co Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Co Llc filed Critical Pharmacia & Upjohn Co Llc
Publication of NO20044672L publication Critical patent/NO20044672L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/422Oxazoles not condensed and containing further heterocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18Oxygen atoms
    • C07D263/20Oxygen atoms attached in position 2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/4211,3-Oxazoles, e.g. pemoline, trimethadione
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
NO20044672A 2002-03-29 2004-10-28 Parenteral, intravenos og oral administrering av oksazolidinoner for behandling av diabetiske fotinfeksjoner NO20044672L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36910402P 2002-03-29 2002-03-29
PCT/US2003/008882 WO2003084534A1 (en) 2002-03-29 2003-03-21 Parenteral, intravenous, and oral administration of oxazolidinones for treating diabetic foot infections

Publications (1)

Publication Number Publication Date
NO20044672L true NO20044672L (no) 2004-12-23

Family

ID=28791924

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20044672A NO20044672L (no) 2002-03-29 2004-10-28 Parenteral, intravenos og oral administrering av oksazolidinoner for behandling av diabetiske fotinfeksjoner

Country Status (16)

Country Link
US (1) US20030216330A1 (https=)
EP (1) EP1490059A1 (https=)
JP (1) JP2005527575A (https=)
KR (1) KR20040095328A (https=)
CN (1) CN1642543A (https=)
AU (1) AU2003223334A1 (https=)
BR (1) BR0308806A (https=)
CA (1) CA2476545A1 (https=)
IL (1) IL164195A0 (https=)
MX (1) MXPA04009356A (https=)
NO (1) NO20044672L (https=)
NZ (1) NZ535648A (https=)
PL (1) PL372661A1 (https=)
RU (1) RU2354372C2 (https=)
WO (1) WO2003084534A1 (https=)
ZA (1) ZA200407734B (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200404069A (en) * 2002-06-28 2004-03-16 Upjohn Co Difluorothioacetamides of oxazolidinones with a glycoloylpiperazine substituent
JP4579502B2 (ja) * 2003-05-02 2010-11-10 キヤノン株式会社 構造体及びその製造方法、該構造体を含むトナー並びにそれを用いた画像形成方法及び装置
US8324398B2 (en) 2003-06-03 2012-12-04 Rib-X Pharmaceuticals, Inc. Process for the synthesis of biaryl oxazolidinones
JP5043428B2 (ja) 2003-06-03 2012-10-10 リブ−エックス ファーマシューティカルズ,インコーポレイテッド ビアリール複素環式化合物ならびにその製造および使用方法
AR046782A1 (es) * 2003-12-17 2005-12-21 Rib X Pharmaceuticals Inc Compuestos heterociclicos de biarilo halogenados, composiciones farmaceuticas que los contienen, metodos para su elaboracion y su uso como medicamentos.
WO2006008640A1 (en) * 2004-07-15 2006-01-26 Pharmacia & Upjohn Company Llc Non-aqueous suspension containing a drug having an unpleasant taste
PE20060619A1 (es) * 2004-07-29 2006-07-11 Ferrer Int Derivados de oxazolidinona como antibacterianos
DE602006019870D1 (de) 2005-06-08 2011-03-10 Rib X Pharmaceuticals Inc Verfahren zur synthese von triazolen
EP1745784A1 (en) * 2005-06-27 2007-01-24 Ferrer Internacional, S.A. Oxazolidinone derivatives and use thereof as antibiotics
WO2007000644A1 (en) 2005-06-29 2007-01-04 Pharmacia & Upjohn Company Llc Homomorpholine oxazolidinones as antibacterial agents
US9427468B2 (en) * 2007-08-22 2016-08-30 Trustees Of Dartmouth College Compositions and methods for diagnosing and treating community-acquired methicillin-resistant Staphylococcus aureus
UY32493A (es) * 2009-03-16 2010-10-29 Astrazeneca Ab " (5r)-3-[4-[1-[(2s)-2,3-dihidroxipropanoil]-3,6-dihidro-2h-piridin-4-il]-3,5-difluorofenil]-5-(isoxazol-3-iloximetil)oxazolidin-2-ona, sus sales farmacéuticamente aceptables, sus ésteres hidrolizables y aplicaciones"
US9795601B2 (en) * 2010-12-15 2017-10-24 Biovista, Inc. Compositions and methods for cancer treatment

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4705799A (en) * 1983-06-07 1987-11-10 E. I. Du Pont De Nemours And Company Aminomethyl oxooxazolidinyl benzenes useful as antibacterial agents
US5043443A (en) * 1988-07-29 1991-08-27 Du Pont Merck Pharmaceutical Company Aminomethyloxooxazolidinyl arylbenzene derivatives
US5254577A (en) * 1988-07-29 1993-10-19 The Du Pont Merck Pharmaceutical Company Aminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents
US5182403A (en) * 1988-09-15 1993-01-26 The Upjohn Company Substituted 3(5'indazolyl) oxazolidin-2-ones
US5225565A (en) * 1988-09-15 1993-07-06 The Upjohn Company Antibacterial 3-(fused-ring substituted)phenyl-5β-amidomethyloxazolidin-2-ones
US5164510A (en) * 1988-09-15 1992-11-17 The Upjohn Company 5'Indolinyl-5β-amidomethyloxazolidin-2-ones
US5231188A (en) * 1989-11-17 1993-07-27 The Upjohn Company Tricyclic [6.5.51]-fused oxazolidinone antibacterial agents
ATE146783T1 (de) * 1991-11-01 1997-01-15 Upjohn Co Substituierte aryl- und heteroaryl- phenyloxazolidinone
SK283420B6 (sk) * 1992-05-08 2003-07-01 Pharmacia & Upjohn Company Antimikrobiálne oxazolidinóny obsahujúce substituované diazínové skupiny
EP0673370B1 (en) * 1992-12-08 1998-01-07 PHARMACIA & UPJOHN COMPANY Tropone-substituted phenyloxazolidinone antibacterial agents
US5688792A (en) * 1994-08-16 1997-11-18 Pharmacia & Upjohn Company Substituted oxazine and thiazine oxazolidinone antimicrobials
EP0730591B1 (en) * 1993-11-22 1999-07-14 PHARMACIA & UPJOHN COMPANY Esters of substituted-hydroxyacetyl piperazine phenyl oxazolidinones
DE4425612A1 (de) * 1994-07-20 1996-04-04 Bayer Ag 6-gliedrige stickstoffhaltige Heteroaryl-oxazolidinone
DE4425609A1 (de) * 1994-07-20 1996-01-25 Bayer Ag Benzofuranyl- und Benzothienyloxazolidinone
DE4425613A1 (de) * 1994-07-20 1996-01-25 Bayer Ag 5-gliedrige Heteroaryl-oxazolidinone
DE19514313A1 (de) * 1994-08-03 1996-02-08 Bayer Ag Benzoxazolyl- und Benzothiazolyloxazolidinone
BR9509673A (pt) * 1994-11-15 1997-09-30 Upjohn Co Compostos e uso dos mesmos
HRP960159A2 (en) * 1995-04-21 1997-08-31 Bayer Ag Benzocyclopentane oxazolidinones containing heteroatoms
RU2175324C2 (ru) * 1995-09-01 2001-10-27 Фармация Энд Апджон Компани Фенилоксазолидиноны, имеющие с-с-связь с 4-8-членными гетероциклическими кольцами
DE19601264A1 (de) * 1996-01-16 1997-07-17 Bayer Ag Pyrido-annellierte Thienyl- und Furanyl-Oxazolidinone
DE19604223A1 (de) * 1996-02-06 1997-08-07 Bayer Ag Neue substituierte Oxazolidinone
KR20010015910A (ko) * 1998-01-23 2001-02-26 로렌스 티. 마이젠헬더 옥사졸리디논 조합 라이브러리, 조성물 및 제조 방법
MY122454A (en) * 1998-06-05 2006-04-29 Upjohn Co Use of oxazolidinones for the preparation of a medicament for transdermal delivery
ES2245698T3 (es) * 2000-06-30 2006-01-16 PHARMACIA & UPJOHN COMPANY LLC Composiciones para el tratamiento de infecciones bacterianas que contienen un compuesto de oxazolidinona, sulbactam y ampicilina.

Also Published As

Publication number Publication date
NZ535648A (en) 2007-05-31
PL372661A1 (en) 2005-07-25
CA2476545A1 (en) 2003-10-16
AU2003223334A1 (en) 2003-10-20
CN1642543A (zh) 2005-07-20
KR20040095328A (ko) 2004-11-12
EP1490059A1 (en) 2004-12-29
WO2003084534A1 (en) 2003-10-16
US20030216330A1 (en) 2003-11-20
RU2004131830A (ru) 2005-04-10
BR0308806A (pt) 2005-01-04
MXPA04009356A (es) 2005-01-25
ZA200407734B (en) 2005-06-24
IL164195A0 (en) 2005-12-18
RU2354372C2 (ru) 2009-05-10
JP2005527575A (ja) 2005-09-15

Similar Documents

Publication Publication Date Title
NO20044672L (no) Parenteral, intravenos og oral administrering av oksazolidinoner for behandling av diabetiske fotinfeksjoner
CY1125077T1 (el) Αγωγη της ανεπαρκειας και ελλειψης βιταμινης d με 25-υδροξυβιταμινη d2 και 25-υδροξυβιταμινη d3
CO5700796A2 (es) Composiciones que contienen piperacilina y tazobactam utiles para inyecciones
NO20034549D0 (no) Behandling av type 2 diabetes med inhibitorer av dipeptidyl peptidase IV
NO20075042L (no) Farmasoytisk sammensetning innbefattende en omega-karboksyarylsubstituert difenylurea for behandling av cancer
BRPI0408784A (pt) método para usar um composto
WO2004032909A3 (en) Stabilized pharmaceutical composition containing basic excipients
HUP0300725A2 (hu) Az inzulinrezisztencia-szindróma kezelése CGMP PDE5 inhibitorokkal
EP2279244A4 (en) METHOD AND COMPOSITIONS FOR ORAL ADMINISTRATION OF PROTEINS
BR0307066A (pt) Dispositivo médico resistente a infecção
BRPI0409523A (pt) método para o tratamento da dor neuropática, método de identificação de um composto e composição farmacêutica
BRPI0415953A (pt) formulação de dosagem de liberação controlada oral, método de tratamento de um distúrbio, conjunto de formas de dosagem de liberação controlada e método para administração da formulação
CY1106771T1 (el) Φαρμακευτικη συνθεση η οποια χρησιμοποιειται για τον ελεγχο της γλυκοζης του αιματος σε ασθενεις με διαβητη τυπου 2
NO20064547L (no) Fremgangsmater for behandling av HIV infeksjon
ATE357928T1 (de) Pharmazeutische zusammensetzung für thrombinpeptidderivaten
CY1108599T1 (el) Η απλιδινη στην αντιμετωπιση του πολλαπλου μυελωματος
BR0110382A (pt) Utilização de composições antibióticas azalida para o tratamento ou prevenção de uma infecção causada por bactérias ou protozoários em mamìferos
CL2024003328A1 (es) Métodos para el tratamiento de linfoma.
BRPI0517650A (pt) uso de ranolazina em combinação com pelo menos um agente de remodelamento para reversão de remodelamento ventricular esquerdo no tratamento de insuficiência cardìaca
DK1096934T3 (da) Oxazolidinoner til behandling af öjeninfektioner
BRPI0414518A (pt) composições farmacêuticas e métodos compreendendo combinações de derivados de 2-alquilideno-19-nor-vitamina d e hormÈnio paratireoidiano
PL1648473T3 (pl) Pojedyncza dawka szybko rozpuszczającej się azytromycyny
NO20080495L (no) PEG-IFN-alfa og ribavirin for HBV-behandling
DK1532279T3 (da) Fremgangsmåde, sammensætning og kit til antigenbinding af Norwalk-lignende vira
NO20006161L (no) Topisk tilförsel av oksazolidinoner for transdermal levering

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application